JP-Compliant Analysis of Impurities of COVID-19 Drug Dexamethasone

Significance of the topic

Impurity profiling of pharmaceutical compounds such as dexamethasone is essential for guaranteeing patient safety and drug efficacy. Regulatory authorities, including the Japanese Pharmacopoeia, mandate thorough analysis of related substances to detect potential contaminants and degradation products. A reliable, pharmacopeia-compliant method supports quality control, batch release, and stability studies, especially for critical drugs used in COVID-19 treatment.

Objectives and overview

This application note aims to present a reversed-phase HPLC method using a VP-phenyl column for the determination of dexamethasone and its impurities, in line with Japanese Pharmacopoeia (JP) purity requirements. The study demonstrates method robustness, selectivity, and sensitivity, providing an overview of chromatographic conditions, system suitability, and assay performance for routine QC implementation.

Methodology and instrumentation

The analysis was conducted on a Shimadzu Nexera lite system with the following conditions:

• Column: Shim-pack VP-phenyl, 250 × 4.6 mm i.d., 5 µm
• Mobile phase: 1.32 g/L ammonium formate buffer (pH 3.6, adjusted with formic acid) and acetonitrile (67:33, v/v)
• Flow rate: 1.15 mL/min
• Column temperature: 25 °C
• Injection volume: 10 µL
• Detection: UV at 254 nm
• Sample vials: TORAST-HTM 1.5 mL amber glass with cap and septa

Main results and discussion

The method achieved clear separation of dexamethasone from its related substances within a 15-minute run time. A standard solution of 5.94 mg/L dexamethasone produced a distinct peak with high signal-to-noise ratio. System suitability tests confirmed acceptable resolution, peak symmetry, and retention time reproducibility (RSD < 1%). The phenyl phase demonstrated specific π-π interactions that enhanced selectivity for aromatic impurities prevalent in synthetic routes.

Benefits and practical applications

• Pharmacopeial compliance: Fully meets JP requirements for related substances.
• Reproducibility: Consistent retention times and resolution across batches.
• Speed: Short analysis time supports high sample throughput.
• User-friendly: Simple mobile phase preparation and standard HPLC setup.

Future trends and possibilities

Advancements may include adoption of UHPLC for faster separations, integration of mass spectrometric detection for mass confirmation of unknown impurities, and the use of greener solvents to minimize environmental impact. Automated sample preparation and data processing with machine learning can further streamline impurity profiling in pharmaceutical QC laboratories.

Conclusion

The described reversed-phase HPLC method using a Shim-pack VP-phenyl column provides a robust, sensitive, and JP-compliant approach for the analysis of dexamethasone and its related impurities. Its simplicity and performance make it suitable for routine quality control in pharmaceutical production.

References

• Application News L584, Shimadzu Corporation (JP, ENG)